Yesterday, Mylan filed two petitions for inter partes review of Genentech’s U.S. Patent No. 6,407,213. According the petitions, the patent is directed to humanized antibodies, and Mylan expects that Genentech will rely on data regarding Herceptin® (trastuzumab) in its arguments regarding secondary considerations. We will continue to monitor and report on updates for IPR2016-01693 and IPR2016-01694 on our IPR tracker page.
Blog Big Molecule Watch August 31, 2016